284 related articles for article (PubMed ID: 31652556)
1. The Effect of Biotinylated PAMAM G3 Dendrimers Conjugated with COX-2 Inhibitor (celecoxib) and PPARγ Agonist (Fmoc-L-Leucine) on Human Normal Fibroblasts, Immortalized Keratinocytes and Glioma Cells in Vitro.
Uram Ł; Misiorek M; Pichla M; Filipowicz-Rachwał A; Markowicz J; Wołowiec S; Wałajtys-Rode E
Molecules; 2019 Oct; 24(20):. PubMed ID: 31652556
[TBL] [Abstract][Full Text] [Related]
2. Biotinylated PAMAM G3 dendrimer conjugated with celecoxib and/or Fmoc-l-Leucine and its cytotoxicity for normal and cancer human cell lines.
Uram Ł; Filipowicz A; Misiorek M; Pieńkowska N; Markowicz J; Wałajtys-Rode E; Wołowiec S
Eur J Pharm Sci; 2018 Nov; 124():1-9. PubMed ID: 30118847
[TBL] [Abstract][Full Text] [Related]
3. Repurposed Drugs Celecoxib and Fmoc-L-Leucine Alone and in Combination as Temozolomide-Resistant Antiglioma Agents-Comparative Studies on Normal and Immortalized Cell Lines, and on
Uram Ł; Pieńkowska N; Misiorek M; Szymaszek Ż; Twardowska M; Siorek M; Wołowiec S
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542198
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
Uram Ł; Markowicz J; Misiorek M; Filipowicz-Rachwał A; Wołowiec S; Wałajtys-Rode E
Eur J Pharm Sci; 2020 Sep; 152():105439. PubMed ID: 32615261
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Different Effects of Biotinylated PAMAM G3 Dendrimer Substituted with Nimesulide in Human Normal Fibroblasts and Squamous Carcinoma Cells.
Uram Ł; Filipowicz-Rachwał A; Misiorek M; Winiarz A; Wałajtys-Rode E; Wołowiec S
Biomolecules; 2019 Sep; 9(9):. PubMed ID: 31480608
[TBL] [Abstract][Full Text] [Related]
6. Cellular uptake of glucoheptoamidated poly(amidoamine) PAMAM G3 dendrimer with amide-conjugated biotin, a potential carrier of anticancer drugs.
Uram Ł; Szuster M; Filipowicz A; Zaręba M; Wałajtys-Rode E; Wołowiec S
Bioorg Med Chem; 2017 Jan; 25(2):706-713. PubMed ID: 27919613
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of Biotinylated PAMAM G3 Dendrimers Substituted with
Wróbel K; Wołowiec S; Markowicz J; Wałajtys-Rode E; Uram Ł
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158983
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma.
Badawi AF; Eldeen MB; Liu Y; Ross EA; Badr MZ
Cancer Res; 2004 Feb; 64(3):1181-9. PubMed ID: 14871855
[TBL] [Abstract][Full Text] [Related]
9. COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Majchrzak-Celińska A; Misiorek JO; Kruhlenia N; Przybyl L; Kleszcz R; Rolle K; Krajka-Kuźniak V
BMC Cancer; 2021 May; 21(1):493. PubMed ID: 33941107
[TBL] [Abstract][Full Text] [Related]
10. Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib.
Ramer R; Walther U; Borchert P; Laufer S; Linnebacher M; Hinz B
J Lipid Res; 2013 Nov; 54(11):3116-29. PubMed ID: 23943857
[TBL] [Abstract][Full Text] [Related]
11. Mixed-Generation PAMAM G3-G0 Megamer as a Drug Delivery System for Nimesulide: Antitumor Activity of the Conjugate Against Human Squamous Carcinoma and Glioblastoma Cells.
Zaręba M; Sareło P; Kopaczyńska M; Białońska A; Uram Ł; Walczak M; Aebisher D; Wołowiec S
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31601050
[TBL] [Abstract][Full Text] [Related]
12. Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer.
Mustafa A; Kruger WD
Clin Cancer Res; 2008 Aug; 14(15):4935-42. PubMed ID: 18676768
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant human gastric cancer cells by inhibition of cyclooxygenase-2.
Xu HB; Shen FM; Lv QZ
Eur J Pharmacol; 2015 Dec; 769():1-7. PubMed ID: 26407653
[TBL] [Abstract][Full Text] [Related]
14. Interaction of epidermal growth factor with COX-2 products and peroxisome proliferator-activated receptor-γ system in experimental rat Barrett's esophagus.
Majka J; Wierdak M; Szlachcic A; Magierowski M; Targosz A; Urbanczyk K; Krzysiek-Maczka G; Ptak-Belowska A; Bakalarz D; Magierowska K; Chmura A; Brzozowski T
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G375-G389. PubMed ID: 31928220
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of celecoxib in lung carcinoma by regulation of cyclooxygenase-2/cytosolic phospholipase A₂ and peroxisome proliferator-activated receptor gamma.
Zhang M; Xu ZG; Shi Z; Shao D; Li O; Li W; Li ZJ; Wang KZ; Chen L
Mol Cell Biochem; 2011 Sep; 355(1-2):233-40. PubMed ID: 21559762
[TBL] [Abstract][Full Text] [Related]
16. Biotin Transport-Targeting Polysaccharide-Modified PAMAM G3 Dendrimer as System Delivering α-Mangostin into Cancer Cells and
Markowicz J; Uram Ł; Wołowiec S; Rode W
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884739
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells.
Sugimoto T; Bartholomeusz C; Tari AM; Ueno NT
Breast Cancer Res; 2007; 9(4):R41. PubMed ID: 17612393
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors.
Kusunoki N; Yamazaki R; Kawai S
Arthritis Rheum; 2002 Dec; 46(12):3159-67. PubMed ID: 12483719
[TBL] [Abstract][Full Text] [Related]
19. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
